权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Actigraphic assessment of sleep quality in the A4 trial

A4 试验中睡眠质量的活动记录评估

基本信息

批准号：
8871221
负责人：
PAUL B ROSENBERG
金额：
$ 36.27万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-15 至 2020-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8871221
关键词：
Active Immunization Address Affect Aging Aging-Related Process Alzheimer&apos s Disease Amyloid Amyloid deposition Area Beds Biological Markers Brain Cerebrospinal Fluid Circadian Rhythms Clinical Communities Complement Consent Data Deposition Drosophila melanogaster Elderly Enrollment Etiology Exhibits Human Individual Intravenous infusion procedures Measures Memory Disorders Methods Modeling Mus Observational Study Outcome Parents Participant Pathology Patient Self-Report Patients Persons Pittsburgh Compound-B Placebos Positron-Emission Tomography Prevention Prevention therapy Prevention trial Proxy Public Health Quality of life Randomized Randomized Controlled Trials Recruitment Activity Reporting Research Rest Risk Sampling Scanning Senile Plaques Sleep Sleep Fragmentations Sleep disturbances Therapeutic Intervention Time Wrist abeta accumulation actigraphy awake cost follow-up functional decline human very old age (85+)improved mouse model pre-clinical public health relevance sleep onset therapy development

项目摘要

DESCRIPTION (provided by applicant): The Anti-Amyloid Treatment of Asymptomatic Alzheimer's Disease (A4) parent trial is a trial of anti-amyloid therapy for prevention of cognitiv decline in 1000 participants who are cognitively healthy, 65-85 years old, and have evidence of amyloid in their brain on flobetapir PET scans. Quality of sleep is important for quality of life ad there is evidence for poorer sleep quality in older persons and in persons at risk of developing Alzheimer's disease. Actigraphy is a low-cost noninvasive method of measuring activity validated for assessing sleep quality, using an accelerometer that is worn like a wristwatch. We propose to add actigraphic assessment of sleep quality in 50 amyloid-positive and 50 amyloid-negative participants who have consented to A4. We hope to assess the effect of anti-amyloid therapy on sleep quality, and the effect of baseline amyloid status on changes in sleep in the placebo and amyloid-negative group.

描述(由申请人提供)：抗淀粉样蛋白治疗无症状阿尔茨海默病(A4)家长试验是一项针对1000名认知健康、年龄在65-85岁之间、在FLOBETAPIR PET扫描中有淀粉样蛋白证据的参与者进行的预防Cognitiv下降的抗淀粉样蛋白治疗试验。睡眠质量对生活质量很重要，有证据表明老年人和阿尔茨海默病高危人群的睡眠质量较差。肌动记录仪是一种低成本、非侵入性的活动测量方法，可用于评估睡眠质量，它使用的是像手表一样佩戴的加速度计。我们建议在同意A4的50名淀粉样阳性和50名淀粉样阴性参与者中增加睡眠质量的动态评估。我们希望评估抗淀粉样蛋白治疗对睡眠质量的影响，以及在安慰剂和淀粉样蛋白阴性组中，基线淀粉样蛋白状态对睡眠变化的影响。